post-traumatic stress disorder

Three former crew members of the Thailand-flagged ship Mayuree Naree sued Precious Shipping Co. and affiliated entities over labor rights violations and unfair dismissal after the vessel was attacked in the Strait of Hormuz in March 2026. The lawsuit alleges the defendants endangered lives by sailing through a high-risk area and dismissed the crew before contract completion, citing inadequate compensation and PTSD diagnoses.

Three former crew members of a Thai cargo ship attacked in the Strait of Hormuz sued the vessel’s operator, Precious Shipping Co., for labor rights violations and unfair dismissal. The ship, Mayuree Naree, was struck by a projectile in March, killing three crew members and leaving the remaining 20 stranded before being rescued. The lawsuit alleges the company endangered lives by sailing through the conflict-ridden strait and dismissed the plaintiffs prematurely after the attack.

Three former crew members of a Thai cargo ship attacked in the Strait of Hormuz sued the vessel’s operator, Precious Shipping Co., alleging labor rights violations and unfair dismissal after the ship was struck by a projectile in March. The lawsuit claims the company endangered their lives by sailing through a high-risk area and dismissed them before their contracts ended, with compensation deemed inadequate due to post-traumatic stress disorder.

A North Carolina veteran described ibogaine as a turning point in his life after serving in the Army during Afghanistan and Iraq wars. He sought psychedelic-assisted therapy through Veterans Exploring Treatment Solutions (VETS) and received treatment in Mexico, where ibogaine is available despite being illegal in the U.S.

Graham Platner, a combat veteran, has been described by several women who dated him as exhibiting unsettling behavior. He has publicly discussed his past struggles with post-traumatic stress disorder, depression, and drinking, stating his past behavior does not reflect his current self.

Rep. Alexandria Ocasio-Cortez has not commented on new allegations against Maine Senate candidate Graham Platner, including claims of aggressive behavior and a Nazi-associated tattoo. Multiple women allege Platner engaged in explicit messaging while married, violent incidents, and expressed violent fantasies. Platner acknowledged past struggles with PTSD and alcohol use but disputes the tattoo's Nazi connotations.

Maine Senate candidate Graham Platner faces allegations from ex-girlfriends, including rape fantasies, violent behavior, and a Nazi-linked tattoo. Platner acknowledges past struggles with PTSD and alcohol but denies further misconduct, calling criticisms politically motivated.

Several women who dated Graham Platner recall 'unsettling' behavior. Platner, a combat veteran, has discussed past struggles with post-traumatic stress disorder, depression, and drinking, stating his behavior years ago does not reflect his current self.

The FDA granted fast-track review to three companies studying psychedelic therapies for depression and PTSD, with two focusing on psilocybin for treatment-resistant depression and major depressive disorder. This move aligns with the Trump administration's push for potential approval of psychedelic treatments.

The FDA has expedited the review of three experimental psychedelic drugs intended to treat major depression and post-traumatic stress disorder. NBC News' Erika Edwards highlights the FDA's evaluation process for safety and efficacy of these drugs.

President Trump signed an executive order to ease U.S. restrictions on psychedelic research, including ibogaine, a drug used in some countries to treat post-traumatic stress disorder.

President Donald Trump signed an executive order directing the FDA to expedite the review of psychedelic drugs like ibogaine, which U.S. military veteran groups claim can treat post-traumatic stress disorder (PTSD). The reform aims to accelerate access to medical research and treatment involving psychedelic substances.

Donald Trump is reportedly set to sign an executive order aimed at easing access to a psychedelic drug for treating post-traumatic stress disorder (PTSD). The move seeks to streamline regulatory barriers for patients seeking alternative therapies.